合計 50 件の最近のインサイダー取引記録が記録されています Apellis Pharmaceuticals, Inc. (APLS), 内訳は 17 件の買い および 30 件の売り. インサイダー買い総額は $2.58M インサイダー売り総額は $3.11M.
最近活動のある主要インサイダーには Biogen Inc., Francois Cedric, Dolsten Mikael. インサイダー取引記録は、経営陣が株式の評価と将来の見通しをどう見ているかについての洞察を提供します.
インサイダー取引記録 — APLS
| 日付 |
氏名 |
役職 |
取引種別 |
株数 |
平均価格 |
価値 |
保有株数 |
| 2026-03-31 |
Biogen Inc. |
Other: See Footnotes |
不明 |
- |
- |
- |
- |
| 2026-03-11 |
Francois Cedric |
Chief Executive Officer |
贈与（受領） |
64,869 |
- |
- |
372,815 |
| 2026-03-02 |
Dolsten Mikael |
Director |
不明 |
- |
- |
- |
- |
| 2026-02-27 |
Dolsten Mikael |
Director |
RSU 付与（制限付株式） |
14,312 |
- |
- |
14,312 |
| 2026-02-11 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
情報に基づく売り |
368 |
$22.15 |
$8.15K |
114,591 |
| 2026-02-03 |
Francois Cedric |
Chief Executive Officer |
オプション行使（売却） |
8,840 |
$3.76 |
$33.24K |
- |
| 2026-01-28 |
Watson David O. |
General Counsel |
RSU 付与（制限付株式） |
55,986 |
- |
- |
144,517 |
| 2026-01-28 |
Deschatelets Pascal |
Chief Scientific Officer |
RSU 付与（制限付株式） |
25,840 |
- |
- |
1,177,222 |
| 2026-01-28 |
Francois Cedric |
Chief Executive Officer |
RSU 付与（制限付株式） |
195,952 |
- |
- |
481,997 |
| 2026-01-28 |
Sullivan Timothy Eugene |
Chief Financial Officer |
RSU 付与（制限付株式） |
58,140 |
- |
- |
152,041 |
| 2026-01-28 |
Nicholson Nur |
Chief Technical Officer |
RSU 付与（制限付株式） |
45,220 |
- |
- |
116,338 |
| 2026-01-28 |
Chopas James George |
VP/chief Accounting Officer |
RSU 付与（制限付株式） |
16,150 |
- |
- |
65,955 |
| 2026-01-28 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
RSU 付与（制限付株式） |
36,606 |
- |
- |
114,959 |
| 2026-01-28 |
Boucher Kelley |
Chief People Officer |
RSU 付与（制限付株式） |
30,146 |
- |
- |
127,804 |
| 2026-01-28 |
Meltzer Leslie |
Chief Research and Development |
RSU 付与（制限付株式） |
45,220 |
- |
- |
107,024 |
| 2026-01-22 |
Watson David O. |
General Counsel |
情報に基づく売り |
7,832 |
$21.77 |
$170.47K |
88,531 |
| 2026-01-22 |
Deschatelets Pascal |
Chief Scientific Officer |
情報に基づく売り |
5,928 |
$21.77 |
$129.03K |
1,151,382 |
| 2026-01-22 |
Francois Cedric |
Chief Executive Officer |
情報に基づく売り |
27,192 |
$21.77 |
$591.84K |
286,045 |
| 2026-01-22 |
Sullivan Timothy Eugene |
Chief Financial Officer |
情報に基づく売り |
10,287 |
$21.77 |
$223.9K |
93,901 |
| 2026-01-22 |
Nicholson Nur |
Chief Technical Officer |
情報に基づく売り |
7,725 |
$21.77 |
$168.14K |
71,118 |
| 2026-01-22 |
Chopas James George |
VP/chief Accounting Officer |
情報に基づく売り |
2,064 |
$21.77 |
$44.92K |
49,805 |
| 2026-01-22 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
情報に基づく売り |
3,371 |
$21.77 |
$73.37K |
78,353 |
| 2026-01-22 |
Baumal Caroline |
Chief Medical Officer |
情報に基づく売り |
2,797 |
$21.77 |
$60.88K |
86,527 |
| 2026-01-20 |
Watson David O. |
General Counsel |
情報に基づく売り |
2,475 |
$19.79 |
$48.99K |
96,363 |
| 2026-01-20 |
Deschatelets Pascal |
Chief Scientific Officer |
情報に基づく売り |
909 |
$19.79 |
$17.99K |
1,157,310 |
| 2026-01-20 |
Francois Cedric |
Chief Executive Officer |
情報に基づく売り |
8,182 |
$19.79 |
$161.95K |
313,237 |
| 2026-01-20 |
Sullivan Timothy Eugene |
Chief Financial Officer |
情報に基づく売り |
2,892 |
$19.79 |
$57.24K |
104,188 |
| 2026-01-20 |
Nicholson Nur |
Chief Technical Officer |
情報に基づく売り |
2,203 |
$19.79 |
$43.6K |
78,843 |
| 2026-01-20 |
Chopas James George |
VP/chief Accounting Officer |
情報に基づく売り |
726 |
$19.79 |
$14.37K |
51,869 |
| 2026-01-20 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
情報に基づく売り |
1,334 |
$19.79 |
$26.4K |
81,724 |
| 2026-01-20 |
Baumal Caroline |
Chief Medical Officer |
情報に基づく売り |
1,882 |
$19.79 |
$37.25K |
89,324 |
| 2026-01-13 |
Watson David O. |
General Counsel |
情報に基づく売り |
5,780 |
$22.19 |
$128.24K |
98,838 |
| 2026-01-13 |
Deschatelets Pascal |
Chief Scientific Officer |
情報に基づく売り |
2,277 |
$22.19 |
$50.52K |
1,158,219 |
| 2026-01-13 |
Francois Cedric |
Chief Executive Officer |
情報に基づく売り |
10,186 |
$22.19 |
$226K |
321,419 |
| 2026-01-13 |
Sullivan Timothy Eugene |
Chief Financial Officer |
情報に基づく売り |
3,856 |
$22.19 |
$85.55K |
107,080 |
| 2026-01-13 |
Nicholson Nur |
Chief Technical Officer |
情報に基づく売り |
2,618 |
$22.19 |
$58.09K |
81,046 |
| 2026-01-13 |
Chopas James George |
VP/chief Accounting Officer |
情報に基づく売り |
873 |
$22.19 |
$19.37K |
52,595 |
| 2026-01-13 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
情報に基づく売り |
1,780 |
$22.19 |
$39.49K |
83,058 |
| 2026-01-07 |
Watson David O. |
General Counsel |
オプション行使（売却） |
888 |
$14.95 |
$13.28K |
14,000 |
| 2026-01-05 |
Baumal Caroline |
Chief Medical Officer |
情報に基づく売り |
3,020 |
$25.53 |
$77.1K |
91,206 |
| 2026-01-01 |
Wheeler Craig A |
Director |
RSU 付与（制限付株式） |
14,684 |
$25.12 |
$368.86K |
14,684 |
| 2026-01-01 |
Machiels Alec |
Director |
RSU 付与（制限付株式） |
14,684 |
$25.12 |
$368.86K |
14,684 |
| 2026-01-01 |
Chan Gerald |
Director |
RSU 付与（制限付株式） |
14,684 |
$25.12 |
$368.86K |
14,684 |
| 2026-01-01 |
O'brien Stephanie Monaghan |
Director |
RSU 付与（制限付株式） |
14,684 |
$25.12 |
$368.86K |
14,684 |
| 2026-01-01 |
Dunlop A. Sinclair |
Director |
RSU 付与（制限付株式） |
14,684 |
$25.12 |
$368.86K |
14,684 |
| 2026-01-01 |
Fonteyne Paul R. |
Director |
RSU 付与（制限付株式） |
14,684 |
$25.12 |
$368.86K |
14,684 |
| 2026-01-01 |
Walbert Keli |
Director |
RSU 付与（制限付株式） |
14,684 |
$25.12 |
$368.86K |
14,684 |
| 2025-12-16 |
Watson David O. |
General Counsel |
情報に基づく売り |
5,000 |
$24.49 |
$122.45K |
103,730 |
| 2025-11-17 |
Watson David O. |
General Counsel |
情報に基づく売り |
5,000 |
$20.06 |
$100.3K |
108,730 |
| 2025-10-21 |
Sullivan Timothy Eugene |
Chief Financial Officer |
情報に基づく売り |
10,000 |
$28.03 |
$280.3K |
110,936 |
■ 情報付き — 公開市場取引（最も重要）
■ 情報なし（買い） — 報酬・オプション行使・転換
■ 情報なし（売り） — 源泉徴収・付与売却
■ 中立 — 贈与・信託・失効
